-
Anticancer Research 1998For the past 20 years, our group has treated over 400 cases of malignant effusion by the intraperitoneal injection of streptococcal preparation OK432 (OK-432 therapy)... (Review)
Review
For the past 20 years, our group has treated over 400 cases of malignant effusion by the intraperitoneal injection of streptococcal preparation OK432 (OK-432 therapy) and has investigated extensively the antitumor mechanisms of this therapy. Prospective clinical data has demonstrated that the OK-432 therapy induced a definite reduction of the effusions in around 60% (responders) of cases and significantly prolonged the survival time in patients who responded well. In addition, a definite reduction of original tumor mass volume was found in around 20% of cases. We have shown that OK432-induced neutrophils, lymphocytes, and probably macrophages may play an important role in tumor cell destruction in ascites. Tumor necrosis factor alpha (TNF-alpha)-induced CD11b/CD18 expression on leukocytes and interferon-gamma (IFN-gamma)-induced ICAM-1 expression on tumor cells may play an important role in leukocyte-mediated tumor destruction. It has also been shown that OK-432 induces various cytokines, such as TNF-alpha, TNF-beta, IFN-alpha IFN-gamma, interleukin-1 (IL-1), IL-2, IL-6, IL-12, tumor growth inhibitory factor(s) (TGIF), and possibly unknown apoptosis-inducing factor(s). Some of these cytokines have been adduced as representing the antitumor activity. These data suggest that two pathways of antitumor activity, i.e., cell-mediated and cytokine-mediated, can be induced simultaneously in the peritoneal cavity. OK-432 therapy may be valuable in the management of patients with malignant effusions. Future clinical and basic research should contribute to further progress in OK-432 therapy.
Topics: Antineoplastic Agents; Ascitic Fluid; Forecasting; Humans; Neutrophils; Picibanil; Pleural Effusion, Malignant; Radiography; Survival Rate; Treatment Outcome; Ultrasonography
PubMed: 9854504
DOI: No ID Found -
Otolaryngology--head and Neck Surgery :... Sep 2009OK-432 has been widely used to treat lymphangioma and ranula; however, there are few studies for its use in treatment of branchial cleft cyst (BCC). We conducted this... (Comparative Study)
Comparative Study
OBJECTIVES
OK-432 has been widely used to treat lymphangioma and ranula; however, there are few studies for its use in treatment of branchial cleft cyst (BCC). We conducted this study to evaluate the effectiveness of sclerotherapy using OK-432 in treatment of BCC.
STUDY DESIGN AND SETTING
Case series with planned data collection.
SUBJECTS AND METHODS
From 2004 to 2007, we treated 23 patients with BCC using OK-432 sclerotherapy. Of these 23 patients, 18 had unilocular cysts and five had multilocular cysts. The sizes of the BCCs were measured and compared before and after treatment.
RESULTS
Of the 23 cases, 14 (60.8%) showed complete regression; all of these were unilocular cysts. Of the remaining individuals with unilocular cysts, only one patient failed to show any response. This individual subsequently underwent surgical excision. A total of five patients with multilocular cysts showed no or partial response and subsequently underwent surgical excision. Minor adverse effects including fever and local pain were reported by 13 (56.5%) patients.
CONCLUSION
These results suggest that sclerotherapy using OK-432 is an effective and safe treatment modality for BCC, especially for unilocular cysts. Sclerosing of unilocular BCC with OK-432 should therefore be considered before surgical excision.
Topics: Adolescent; Adult; Antineoplastic Agents; Biopsy, Fine-Needle; Branchioma; Diagnosis, Differential; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Injections, Intralymphatic; Male; Middle Aged; Picibanil; Prospective Studies; Sclerotherapy; Tomography, X-Ray Computed; Treatment Outcome; Young Adult
PubMed: 19716008
DOI: 10.1016/j.otohns.2009.05.022 -
The Japanese Journal of Surgery May 1990We examined whether the Streptococcal preparation OK-432, an immunopotentiating agent, increases immunocompetence of the gut-associated lymphoid system (GALS), inhibits...
Anti-tumor effects of the oral administration of the streptococcal preparation OK-432 (PICIBANIL)--the inhibition of carcinogenesis and growth in rats with ENNG-induced gastrointestinal tumors.
We examined whether the Streptococcal preparation OK-432, an immunopotentiating agent, increases immunocompetence of the gut-associated lymphoid system (GALS), inhibits gastrointestinal carcinogenesis, and has an anti-tumor effect. 14C-labelled OK-432 was orally and intraperitoneally administered to rats, and the distribution of the agent in various organs then serially evaluated. The concentration of OK-432 in Peyer's patches and mesenteric lymph nodes was higher after oral administration than after intraperitoneal administration, and showed a biphasic pattern peaking at 30 minutes and 5 hours following administration, in the Peyer's patches. With regard to immunocompetence, PHA- and PWM-stimulated blastogenesis of lymphocytes derived from the mesenteric lymph nodes and peripheral blood enhanced, and the helper/suppressor T-cell ratio was elevated after the oral administration of OK-432. Moreover, chemotactic activity of peritoneal macrophages was also increased. ENNG-induced gastrointestinal carcinogenesis was observed in 60 per cent of the rats orally administered OK-432 as compared with 88 per cent of the controls. The 13-month survival rate of the rats with gastrointestinal cancer was 50 per cent in those administered OK-432 as compared with 25 per cent in those administered OK-432 as compared with 25 per cent in the controls. When administered orally, the agent prevented reduction in immuno-competence in the course of carcinogenesis, suppressed carcinogenesis, and prolonged the survival of animals with cancer without any of the side effects associated with injection. The oral administration of OK-432 is thus considered to be an effective non-specific immunotherapy against gastro-intestinal malignancies.
Topics: Administration, Oral; Animals; Biological Products; Carcinogens; Digestive System; Gastrointestinal Neoplasms; Immunocompetence; Lymphoid Tissue; Macrophages; Male; Methylnitronitrosoguanidine; Picibanil; Rats; Rats, Inbred Strains; T-Lymphocytes
PubMed: 2359208
DOI: 10.1007/BF02470667 -
Anticancer Research 1987OK-432, an inactivated and lyophilized preparation of a low-virulence strain of Streptococcus pyogenes induced a phagocytosis process in human erythroleukemic K 562...
OK-432, an inactivated and lyophilized preparation of a low-virulence strain of Streptococcus pyogenes induced a phagocytosis process in human erythroleukemic K 562 cells. This process seems to be specific to the cell line, known however as non-phagocytic, and specific to the bacterial preparation. Transmission and scanning electron microscopy confirmed phagocytosis. Increased lysosomal activity was also demonstrated by cytochemical and biochemical criteria. The induction of phagocytosis required an intact cell surface membrane and sialo-glycoproteins seemed to be implied. The phagocytosis was inversely correlated with the erythroid differentiation of the K 562 cell. Hemin-treated K 562 cells and the markedly erythroid K 562 clone showed a decreased level of phagocytosis. The phagocytosis level in a K 562 clone expressing Fc (IgG) receptors was not altered by OK-432. In addition, a weak erythroid K 562 clone expresses the same level of phagocytosis as the total population.
Topics: Acid Phosphatase; Animals; Biological Products; Cell Differentiation; Cell Division; Cell Line; Cell Membrane; Humans; Leukemia; Leukemia L1210; Phagocytosis; Picibanil; Trypsin
PubMed: 3631914
DOI: No ID Found -
Nihon Gan Chiryo Gakkai Shi Jun 1979
Topics: Antineoplastic Agents; Biological Products; Carbazilquinone; Drug Therapy, Combination; Female; Fluorouracil; Humans; Immunotherapy; Mitomycins; Neoplasms; Picibanil
PubMed: 479655
DOI: No ID Found -
Biomedicine & Pharmacotherapy =... May 2019The occurrence of seroma formation and long-term wound healing remain challenging complications after modified radical mastectomy. Sapylin is a drug used to reduce... (Randomized Controlled Trial)
Randomized Controlled Trial
BACKGROUND
The occurrence of seroma formation and long-term wound healing remain challenging complications after modified radical mastectomy. Sapylin is a drug used to reduce seroma formation and enhance wound closure, but these results remain controversial. We aimed to investigate the potential mechanism.
METHODS
A prospective, consecutive cohort study included 120 patients diagnosed with breast cancer who underwent modified radical mastectomy was designed. Patients were randomized into two group, using or not using OK-432 (sixty patients per group) during surgeries. Patients' drainage fluids were collected for three days after surgery. Inflammatory cytokines and chemokines were measured with ELISA assays. The proliferative, migratory, and angiogenic capacity of HUVEC and HFL1 cells HUVEC and HFL1 cells were measured after being treated with drainage fluids.
RESULTS
Our clinic data showed that there was no statistical significance between the two groups in patient characteristics before surgery. However, the outcomes of patients in experimental group were significantly better than those in control group. In vitro studies, the results of ELISA assays showed that several cytokines, including IL-1a, IL-6, TGF-β1, bFGF and VEGF were increased in the drainage fluids treated with Sapylin. The proliferative, migratory, and angiogenic capacity of HUVEC and HFL1 cells were significantly enhanced after being treated with Sapylin group drainage fluids.
CONCLUSION
Sapylin could stimulate the body to secrete a variety of cytokines to promote wound healing by promoting endothelial cell proliferation and migration, angiogenesis and by increasing fibroblast migration and collagen deposition.
Topics: Breast Neoplasms; Cell Movement; Cell Proliferation; Cohort Studies; Collagen; Cytokines; Female; Human Umbilical Vein Endothelial Cells; Humans; Inflammation; Mastectomy; Middle Aged; Neovascularization, Physiologic; Picibanil; Postoperative Complications; Prospective Studies; Seroma; Surgical Wound; Wound Healing
PubMed: 30844656
DOI: 10.1016/j.biopha.2019.108706 -
Pediatric Surgery International Dec 2022Primary spontaneous pneumothorax (PSP) commonly occurs in lean, tall, male children and adolescents. To reduce recurrence rates of PSP, chemical pleurodesis could be... (Observational Study)
Observational Study
BACKGROUND
Primary spontaneous pneumothorax (PSP) commonly occurs in lean, tall, male children and adolescents. To reduce recurrence rates of PSP, chemical pleurodesis could be helpful for patients undergoing video-assisted thoracoscopic surgery (VATS) wedge bullectomy. The efficacy and safety of intraoperative OK-432 (Picibanil) pleurodesis on preventing the recurrence of PSP in pediatric patients remain unclear.
METHODS
It is a retrospective observational study in a single center, between 2014 and 2020, enrolled 48 (8 females) pediatric PSP patients with persistent air leakage at the mean age of 16.3 ± 1.1 years to receive VATS wedge bullectomy and pleural abrasion. Twenty patients received additional intraoperative OK-432 pleurodesis. The clinical characteristics of patients, surgical outcomes, and recurrence rates were analyzed.
RESULTS
The OK-432 group had longer operation time (118.6 ± 35.6 vs. 96.5 ± 23.3 min; p < 0.05) and higher proportion of postoperative fever (75.0% vs. 28.5%; p = 0.015) than the standard group. No serious adverse events were noted and other surgical outcomes in the two groups were comparable. After a mean follow-up period of 18.1 ± 19.1 months, the OK-432 group had a lower recurrence rate compared with the standard group (5% vs. 28.6%; p < 0.05, odds ratio 0.13, 95% confidence interval: 0.01-1.15), but it had no significant difference in statistics on the Kaplan-Meier curves (log-rank p = 0.105).
CONCLUSION
It was the first study that focused on the addition of intraoperative OK-432 pleurodesis for PSP with persistent air leakage in children and adolescents receiving VATS. It demonstrated the efficacy with a low recurrence rate and short-term safety as a single-center experience.
LEVEL OF EVIDENCE
Retrospective review, therapeutic study, Level III.
Topics: Female; Humans; Male; Adolescent; Child; Pleurodesis; Pneumothorax; Picibanil; Treatment Outcome; Recurrence; Thoracic Surgery, Video-Assisted; Retrospective Studies
PubMed: 36575307
DOI: 10.1007/s00383-022-05347-0 -
Respiratory Investigation Sep 2018Pneumothorax occasionally develops in patients with interstitial pneumonia (IP) and is often intractable. As there exists no well-established treatment for pneumothorax...
BACKGROUND
Pneumothorax occasionally develops in patients with interstitial pneumonia (IP) and is often intractable. As there exists no well-established treatment for pneumothorax with IP, we evaluated the efficacy and safety of pleurodesis with OK-432, a lyophilized preparation of Streptococcus pyogenes Su strain that has been inactivated by benzylpenicillin.
METHODS
We retrospectively evaluated the efficacy and safety of pleurodesis using OK-432 in 39 patients treated for IP-related pneumothorax between January 2006 and May 2017. Five to 10 Klinische Einheit (KE) of OK-432 was injected through the chest tube of each patient. Pleurodesis was considered successful if 1) the chest tube was removed without air leaks and 2) there was no recurrence of pneumothorax within 4 weeks after tube removal, and no additional treatment was required.
RESULTS
OK-432 pleurodesis was performed 46 times in 39 patients. The median number of OK-432 intrapleural injections received was 1 (range, 1-6), and median dose was 10 KE (range, 5-55 KE). The success rate was 63% (29/46) and recurrence rate was 17.4% (8/46). Grade 5 adverse events were observed in eight patients, including two patients who developed acute exacerbation of IP. Patients in whom the first OK-432 pleurodesis was successful had a significantly longer median survival time than patients in whom it was unsuccessful (322 days vs. 70 days, p = 0.036).
CONCLUSIONS
Our results show that OK-432 pleurodesis is an effective treatment for pneumothorax associated with IP; however, clinicians should be aware of the possibility of adverse events, especially in patients who are critically ill.
Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Lung Diseases, Interstitial; Male; Middle Aged; Picibanil; Pleurodesis; Pneumothorax; Retrospective Studies; Time Factors; Treatment Outcome; Young Adult
PubMed: 29903606
DOI: 10.1016/j.resinv.2018.05.003 -
The Kurume Medical Journal 1991Fifty-one patients with stage III and IV ovarian adenocarcinoma underwent initial cytoreductive surgery at Kurume University Hospital between January 1982 and October... (Clinical Trial)
Clinical Trial Randomized Controlled Trial
Fifty-one patients with stage III and IV ovarian adenocarcinoma underwent initial cytoreductive surgery at Kurume University Hospital between January 1982 and October 1985. They were assigned postoperatively by randomized trials to immunochemotherapy or chemotherapy alone. Of all 51 patients, long-term results of immunochemotherapy for 43 patients were evaluated versus radicality of initial cytoreductive surgery. As a result, the group of patients treated with immunochemotherapy tended to have a better prognosis than the group of patients treated with chemotherapy alone, whereas no statistical difference was observed between the two groups. Moreover, no significant difference was observed in the monitoring of OKT 4/8 ratio between the two groups. However, immunochemotherapy produced a favorable prognosis in the patients with residual disease of greater than 2 cm in diameter at initial surgery. In conclusion, these data suggested that immunochemotherapy may have some impact on survival of patients with ovarian adenocarcinoma.
Topics: Adenocarcinoma; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Humans; Ovarian Neoplasms; Picibanil
PubMed: 1779605
DOI: 10.2739/kurumemedj.38.173 -
Nowotwory 1982
Clinical Trial
Topics: Adjuvants, Immunologic; Adult; Aged; Biological Products; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Picibanil; Vincristine
PubMed: 6760132
DOI: No ID Found